Virtual Case Studies™ in Chronic Kidney Disease: Optimizing Patient Selection When Considering Non-Steroidal Mineralocorticoid Receptor Antagonists

Released On
October 14, 2021

Expires On
October 14, 2022

Media Type
Internet

Completion Time
105 minutes

Specialty
Cardiology, Endocrinology, Nephrology

Topic(s)
Diabetes, Cardiovascular Disease, Kidney Disease

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

 

This activity is supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc.

Credit Available

  • Physicians — maximum of 1.75 AMA PRA Category 1 Credit(s)
  • Nurses — 1.75 Contact Hours

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This program is intended for Nephrologists, Primary Care Physicians, Endocrinologists, Cardiologists, and Physician Assistants/Nurse Practitioners.

Program Overview

Chronic kidney disease (CKD) is a disease multiplier that increases the risk of stroke and other cardiovascular diseases. Patients with CKD and diabetes have a high risk of complications, including diabetic retinopathy, diabetic foot, anemia, metabolic bone disease, fracture, infection, and neuropathy. Patients given a diagnosis of CKD also have a greater risk of iatrogenic injury from drug therapy, including acute kidney injury, hypoglycemia, and hyperkalemia. Affected patients also have high rates of comorbidities, such as depression and heart failure. Not surprisingly, this burden of complications and comorbidity translates to poor quality of life and substantially higher use of health care resources and associated costs.

This online activity is designed to promote clinical decision-making via virtual case simulations and expert faculty commentary. Clinicians are presented with 2 patient case simulations; each is followed by a panel discussion that addresses main clinical points related to the simulations. In addition, members of the faculty discuss strategies for renal and cardiovascular protection and the importance of multidisciplinary care for patients with CKD.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Incorporate guideline recommended criteria/testing procedures for the diagnosis of DKD
  • Analyze the role of pathophysiologic mechanism of DKD in the progression of cardiorenal dysfunction
  • Develop individualized treatment plans incorporating non-glucose lowering therapies for patients with DKD
  • Identify patient risk factors for developing hyperkalemia with non-glucose lowering therapies

Chair

FACULTY_NAME

 

Faculty

Professor of Medicine
Director, American Heart Association Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, IL

Faculty

FACULTY_NAME

Jon W. Mares, DO

Kidney & Hypertension Associates
Covington, LA

FACULTY_NAME

Biff F. Palmer, MD

Professor of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, TX

FACULTY_NAME

Ileana L Piña, MD, MPH, FAHA, FACC, FHFSA

Adjunct Professor of Epidemiology and Biostats
Case Western University
Population & Quantitative Health Sciences
Clinical Professor of Medicine
Central Michigan University College of Medicine
Mount Pleasant, MI

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.75 Contact Hours.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

George Bakris, MD (Chair)

  • Consultant: Merck, Bayer, Vascular Dynamics, KBP Biosciences, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, AstraZeneca, Quantum Genomics, Horizon Therapeutics, Novo Nordisk.

Jon W. Mares, DO

  • Speakers’ Bureau: Bayer Pharmaceuticals

Biff F. Palmer, MD, has no relevant financial relationships with ineligible companies.

Ileana L Piña, MD, MPH, FAHA, FACC, FHFSA

  • Other Support: Advisory Board: Vifor Pharma, DIAMOND trial.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.